» Articles » PMID: 8014016

Time Trends in the Incidence of Renal Carcinoma: Analysis of Connecticut Tumor Registry Data, 1935-1989

Overview
Journal Int J Cancer
Specialty Oncology
Date 1994 Jul 1
PMID 8014016
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Recent trends in the incidence of renal cancer, stratified by histology, have not been reported. This study utilized data from the Connecticut Tumor Registry (CTR), the oldest population-based cancer registry in the United States, to establish time trends in the incidence of adenocarcinoma and transitional cell carcinoma of the kidney and urinary tract. All 10,209 incident cases of renal cancer reported to the CTR between 1935 and 1989 were analyzed. Regression modelling was employed to determine the effects of age, period, and birth cohort on incidence rates, and to project future trends. The incidence rate of adenocarcinoma increased in females from 0.7/100,000 in 1935-39, to 4.2/100,000 in 1985-89; and in males, from 1.6/100,000 in 1935-39, to 9.6/100,000 in 1985-89. The reported incidence of transitional cell carcinoma increased in males from 0.5/100,000 in 1950-54 to 2.8/100,000 in 1985-89, and in females from 0.2/100,000 to 1.1/100,000 over the same period. Regression modelling revealed that both net and recent drift, the sum of period and cohort slopes, were positive for adenocarcinoma in both sexes, largely due to a positive cohort effect. While the net drift for transitional cell carcinoma was positive, recent drift was negative in both sexes due primarily to a negative cohort effect. Incidence rates of adenocarcinoma are likely to rise in the immediate future, with the rate of rise in females possibly exceeding that in males. Incidence rates of transitional cell carcinoma will stabilize.

Citing Articles

The long-term rapid increase in incidence of adenocarcinoma of the kidney in the USA, especially among younger ages.

Zheng T, Zhu C, Bassig B, Liu S, Buka S, Zhang X Int J Epidemiol. 2019; 48(6):1886-1896.

PMID: 31317187 PMC: 7967823. DOI: 10.1093/ije/dyz136.


Rho GDP dissociation inhibitor-β in renal cell carcinoma.

von Klot C, Dubrowinskaja N, Peters I, Hennenlotter J, Merseburger A, Stenzl A Oncol Lett. 2017; 14(6):8190-8196.

PMID: 29250194 PMC: 5727609. DOI: 10.3892/ol.2017.7233.


Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.

VON Klot C, Merseburger A, Kuczyk M Mol Clin Oncol. 2016; 4(6):903-908.

PMID: 27313856 PMC: 4888023. DOI: 10.3892/mco.2016.856.


The type of nephrectomy has little effect on overall survival or cardiac events in patients of 70 years and older with localized clinical t1 stage renal masses.

Kyung Y, You D, Kwon T, Song S, Jeong I, Song C Korean J Urol. 2014; 55(7):446-52.

PMID: 25045442 PMC: 4101113. DOI: 10.4111/kju.2014.55.7.446.


Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma.

von Klot C, Kramer M, Peters I, Hennenlotter J, Abbas M, Scherer R BMC Clin Pathol. 2014; 14:15.

PMID: 24708743 PMC: 4026056. DOI: 10.1186/1472-6890-14-15.